Starting September/October, 2025 Rejuvenate MedSpa will be switching from Semaglutide to Liraglutide.

What does this mean and why is it happening?

On May 21st, 2025 the FDA removed semaglutide injection products from its drug shortage list, signaling a resolution of the supply issues. This means that for 503B outsourcing facilities, the grace period for compounding and dispensing semaglutide injection products under section 503B of the FD&C Act ended on May 22, 2025. 

Here's a more detailed breakdown:

• Shortage Resolution:
  The FDA declared the shortage of semaglutide injection products, which began in March 2022 for Wegovy and August 2022 for Ozempic, was resolved. 

• End of Compounding:
  State-licensed pharmacies and physicians compounding under section 503A of the FD&C Act can continue to compound and distribute semaglutide until April 22, 2025. Outsourcing facilities under section 503B are permitted to do so until May 22, 2025

What should I know as a patient about my medication going forward?

Both liraglutide and semaglutide are prescription GLP-1 receptor agonist medications used to help lower blood sugar in patients to help people lose weight and keep it off, and to help lower the risk of major heart-related events like a stroke, heart attack or death. These medications also slow gastric emptying, suppress appetite, help control blood sugar levels, and promote insulin secretion. These medicines are typically used in addition to diet and exercise for the most benefit.

This injection will be a daily injection instead of a weekly injection like Semaglutide was. 

*The price of this medication is always subject to change but will not be changing at this time.

Side effects remain the same across both medications which include, but are not limited to, pancreatitis, gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation. These side effects are usually mild and tend to improve over time.